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B-cell ElispotA central, yet unresolved issue in the pathogenesis of HIV disease is the mechanism of antibody
perturbation. In this study, HIV-speciﬁc memory B-cells were quantiﬁed in groups of infected subjects and
compared with memory responses to other antigens and antibody titers. HIV-speciﬁc memory B-cell
responses were vigorous in individuals with CD4+ T-cell counts N350/μl and weak or undetectable in
subjects with CD4+ T-cell numbers b200/μl. Memory B-cell loss was permanent, because antiretroviral
therapy failed to restore HIV-speciﬁc memory responses while inﬂuenza- and tetanus toxoid-speciﬁc
memory B-cells remained unaffected or recovered. Antibody titers to Gag strongly correlated with
memory B-cell frequencies. In contrast, Env-speciﬁc antibodies were maintained in advanced disease
despite low or undetectable levels of memory B-cells. These results provide a potential mechanism by
which destruction of HIV-speciﬁc CD4+ T-cells affects the humoral immune response against HIV and
compromises the ability to maintain an effective antibody response.
© 2009 Elsevier Inc. All rights reserved.Introduction
Infectionwith the human immunodeﬁciency virus (HIV) leads to B-
lymphocyte dysfunction that is already detectable in the primary
phase of the disease (Titanji et al., 2005). Infected individuals show
signs of polyclonal B-cell hyperactivity with hypergammaglobuline-
mia (Lane et al., 1983; Terpstra et al., 1989) and increased frequencies
of activated and terminally differentiated B-cells (Fournier et al., 2002;
Moir et al., 2001; Shirai et al., 1992). Moreover, levels of memory B-
cells in the blood decline (De Milito et al., 2001; Nagase et al., 2001)
and as the disease progresses to AIDS, the B-cell population becomes
poorly responsive tomitogens and common recall antigens (Hart et al.,
2007; Janoff et al., 1991; Jiang et al., 2008; Kroon et al., 2000; Lane et al.,
1983; Malaspina et al., 2005, 2008; Moir et al., 2008a). Initiation of
antiretroviral therapy (ART) reduces B-cell hyperactivity, normalizes09 Keystone Symposium HIV
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ll rights reserved.total B-cell numbers and partially restores the proportion of B-cell
subpopulations in the blood indicating that ongoing viral replication
and low CD4+ T-cell numbers are the major pathogenic factors (Moir
et al., 2008b; Morris et al., 1998). Dysfunction speciﬁcally affects the
HIV-speciﬁc antibody response leading to a decline of anti-Gag
antibody titers in the blood that is not or only weakly responsive to
therapy. It is thought that the decline is a surrogate marker for the loss
of T-cell help, but the mechanism that leads to the fall of antibodies is
incompletely understood. In contrast, Env-speciﬁc antibodies are
maintained and may only decline as frank AIDS develops but the
underlying process is likewise unclear (Binley et al., 1997; Brown et al.,
1995; Cheingsong-Popov et al., 1991; Strathdee et al., 1995; Zwart
et al., 1994).
Viral infections usually induce the generation of memory B-cells in
a process called the germinal center (GC) reaction. Initiation of the GC
reaction requires the help of antigen-speciﬁc CD4+ T-cells (Gourley
et al., 2004). It has been reported that HIV preferentially infects and
progressively depletes HIV-speciﬁc CD4+ T helper cells (Douek et al.,
2002; Pitcher et al., 1999; Rosenberg et al., 1997) suggesting that the
GC reaction and speciﬁcally the development of HIV-speciﬁc memory
B-cells might be affected. However, there is limited knowledge about
HIV-speciﬁc memory B-cells.While previous studies provide evidence
that HIV infection induces virus-speciﬁc memory B-cells (Bonsignori
et al., 2009; Fondere et al., 2003; Guan et al., 2009; Scheid et al., 2009),
8 Rapid Communicationthe effect of HIV disease progression on these cells has not yet been
investigated. One reason for that is that analyses of HIV-speciﬁc
memory B-cells are considered inherently difﬁcult because of the
immune dysfunction associated with HIV pathogenesis (Guan et al.,
2009).
In the present study, we examined the possibilities of permanent
versus transient or reversible loss of HIV-speciﬁc memory B-cell
responses in groups of subjects with different clinical characteristics
including individuals with CD4+ T-cell counts above 350/μl, below
200/μl, and under antiretroviral therapy using a highly sensitive
memory B-cell ELISpot protocol. We compared the results with
memory B-cell responses against inﬂuenza virus and tetanus toxoid
and with antibody titers. Our ﬁndings provide evidence of selective
depletion of HIV-speciﬁc memory B-cells during disease progression
that is not responsive to ART. Moreover, the results demonstrate a




While a better understanding of the HIV-speciﬁc B-cell-mediated
immune response may provide new opportunities to raise the level of
immune protection, current knowledge about the virus-speciﬁc
memory B-cells is limited. To address the question to what extentFig. 1. Viral load and percentage of CD4+ T-cells and B-cell populations. (A) Viral load in the
without and with antiretroviral therapy. Symbols represent values from individual subjec
counts; (C) CD19+ CD20+ CD27+memory B-lymphocytes and (D) CD19+ CD20− CD38hi pla
p-values were calculated using the Kruskal–Wallis (values in boxes) and Mann–Whitney teHIV-speciﬁc memory B-cell responses are affected during disease
progression, we examined the HIV-speciﬁc memory B-cells in groups
of subjects with CD4+ T-cell counts above 350/μl and patients with a
fall of CD4+ T-cell counts to below 200/μl. Subjects with CD4+ T-cell
counts above 350/μl were arranged in groups of individuals with viral
loads smaller (hereafter: controllers, 10 subjects) and greater than
(hereafter: early progressors, 10 subjects) 1,000 RNA copies/ml
plasma (Fig. 1A). Individuals with CD4+ T-cell counts below 200/μl
were grouped in ART untreated (hereafter: late progressors, 8 sub-
jects) and treated (hereafter: treated late progressors, 10 subjects)
individuals. A group of 10 healthy uninfected individuals was added
as control. None of the subjects outside the treated group received
ART.
Treated late progressors received ART for more than 18 months
and had undetectable viral loads or levels below 100 RNA copies/ml
in the three measurements preceding the examination. The median
CD4+ T-cell count in this group was 413 cells/μl. CD4+ T cell numbers
were lower in the untreated late progressor group (Fig. 1B). In
addition, total numbers of memory B-cells were signiﬁcantly lower
and plasma cell frequencies higher than in the groups of uninfected
individuals, controllers, and ART-treated subjects. In contrast,memory
B-cell frequencies and plasma cell numbers in the ART-treated group
were comparable to those in uninfected healthy individuals
(Figs. 1C, D). Together the data show that in the study population
HIV progression led to perturbations of the total memory and plasma
cell frequencies in the blood. ART restored plasma and memory B-cellplasma of viral controllers, subjects with early disease and with late disease progression
ts. Viral load values were signiﬁcantly different between the groups; (B) CD4+ T-cell
sma cells in groups of infected individuals and in healthy uninfected subjects. Statistical
st. Bars indicate median values.
9Rapid Communicationfrequencies together with a reduction of the viral load and an increase
of total helper T-cell numbers.
Loss of Gag- and Env-speciﬁc memory B-cells upon disease progression
We next examined Gag/p24- and Env/gp120-speciﬁc memory B-
cell responses in the HIV-infected subjects of the study groups.
Vigorous Gag-speciﬁc responses were observed in the group of
controllers with a median frequency of 0.5%. In the cohort of subjects
with early progressive disease, the median memory B-cell frequency
was 0.135%. The difference between the two groups was not
signiﬁcant (p=0.198). In contrast, the median frequencies in these
groups were signiﬁcantly higher than in the group of subjects with
late disease progression (median frequency 0.0065%) indicating a loss
of the Gag-speciﬁc memory B-cell responses in individuals with
advanced disease. Particularly notable is that in the treated late
progressor group, Gag-speciﬁc memory B-cell frequencies were as
low as in the untreated group (median frequency 0.019%) indicating
that antiretroviral therapy does not reverse the loss of speciﬁc
memory B-cells (Fig. 2A).
In addition to Gag-speciﬁc memory B-cells, robust Env/gp120-
speciﬁc memory B-cell responses were present in the controller group
(median: 0.111 %), and in the group with early progressive infection
(median: 0.068%) indicating that HIV normally induces vigorous
memory B-cell responses. Similar to the Gag-speciﬁc responses, the
median Env-speciﬁc memory B-cell frequencies in these groups wereFig. 2. Comparison of HIV-speciﬁc memory B-cells in the blood of viral controllers, early
and late disease progressors and late disease progressors receiving ART. (A) Percentage
of Gag/p24 and (B) percentage of Env/gp120-speciﬁc memory B-cells. Kruskal–Wallis
(values in boxes) and Mann–Whitney tests were used to calculate the statistical
signiﬁcance of differences between groups. Open symbols indicate memory B-cell
frequencies below 0.001%. Bars indicate median values.signiﬁcantly higher than those in the late progressor (median
frequency: 0.002%) and ART-treated group (median frequency:
0.005%) (Fig. 2B) indicating progressive and irreversible Env-speciﬁc
memory B-cell loss.
Maintenance of inﬂuenza- and tetanus-speciﬁc memory B-cells in
progressive HIV disease
To investigate whether these data would be reﬂected in other
parts of the B-cell response or whether memory B-cell depletion
was limited to HIV-1-speciﬁc cells, we compared HIV-speciﬁc
responses with those to other common recall antigens such as
inﬂuenza nucleoprotein (NP, Fig. 3A) and tetanus toxoid (Ttx,
Fig. 3B). While it is likely that all individuals had repeatedly been
naturally exposed to inﬂuenza virus, several individuals had also
been immunized against inﬂuenza and all study subjects had pre-
viously been vaccinated against tetanus. Memory B-cell responses
against inﬂuenza and Ttx were not statistically different in the
study groups, although there was a trend towards lower frequencies
in the late progressor group. Notably, the memory B-cell responses
against inﬂuenza and Ttx were normal in the group of ART-treated
subjects.
HIV-speciﬁc antibody titers
Memory B-cells may periodically differentiate into antibody-
secreting long-lived plasma cells to maintain long-term antibody
production (Gourley et al., 2004). We determined the magnitude of
the antibody responses to Gag and Env to examine the association
with memory B-cell frequencies. Vigorous Gag- and Env-speciﬁc
antibody titers were present in the controller and early progressor
groups. However, whereas Env-speciﬁc antibodies remained high in
the late progressor group, there was a trend towards lower levels of
Gag-speciﬁc antibodies in this group compared with the group of
disease controllers (p=0.091). ART signiﬁcantly reduced Env-
speciﬁc antibodies but did not further reduce Gag-speciﬁc antibody
titers (Figs. 4A, B).
Gag-speciﬁc antibody titers correlated highly signiﬁcantlywith the
memory B-cell frequencies indicating an association of the plasma cell
activity with the memory B-cell response. In contrast, memory B-cell
frequencies and antibody responses to Env were divergent. Robust
antibody titers were observed in individuals with advanced disease
despite low or undetectable memory B-cells indicating that at least
some of the Env-speciﬁc antibody response is memory B-cell
independent (Figs. 4C, D).
Discussion
While it is well known that in HIV infection the B-cell population
becomes poorly responsive to common recall antigens indicating
global memory B-cell dysfunction (Janoff et al., 1991; Kroon et al.,
2000; Lane et al., 1983; Malaspina et al., 2005), there is limited
knowledge about HIV-speciﬁc memory B-cells in early and advanced
disease. The results of this study show that HIV induces vigorous
virus-speciﬁc memory B-cell responses in early stages of the
infection (CD4+ T-cell count above 350/μl) and preferential elimi-
nation of HIV-speciﬁc memory B-cells later in the disease (CD4+
T-cell count below 200/μl). In particular, compared with subjects
with CD4+ T-cell counts above 350/μl, individuals with helper T-cell
counts below 200/μl, as a group, had signiﬁcantly lower numbers
of HIV-speciﬁc memory B-cells in the peripheral blood. Moreover,
ART for more than 18 months failed to normalize HIV-speciﬁc
memory B-cell responses suggesting that the cells were depleted
permanently.
Consistent with previous studies that showed an increase of total
memory B-cell numbers after initiation of ART (Moir et al., 2008b;
Fig. 3. Comparison of inﬂuenza virus nucleoprotein- and tetanus toxoid-speciﬁc memory B-cells. (A) Frequency of inﬂuenza NP-speciﬁc and (B) frequency of Ttx-speciﬁc memory
B-cells in the blood. Statistical p-values were calculated using the Kruskal–Wallis non-parametric test. Open symbols indicate values below 0.001%. Bars indicate median
frequencies.
10 Rapid CommunicationMorris et al., 1998) we observed normal total memory B-cell num-
bers in the group of late disease progressors under therapy. Similarly,
in agreement with previous ﬁndings that demonstrated a cor-
relation of inﬂuenza-speciﬁc memory B-cell responses and CD4+
T-cell counts after booster vaccination with an inﬂuenza vaccine
(Malaspina et al., 2005), we observed that memory B-cell responses
to inﬂuenza and Ttx were normal in ART-treated individuals with
partially restored CD4+ T-cell counts. In striking contrast, HIV-
speciﬁc memory B-cell responses were low to absent in the group of
ART-treated subjects despite signiﬁcant increases in CD4+ T-cells. As
the generation of memory B-cells depends on T-cell help, the pre-
ferential loss of HIV-speciﬁc memory B-cells supports the concept of
preferential infection and depletion of HIV-speciﬁc CD4+ T-cells
described previously (Douek et al., 2002; Pitcher et al., 1999;
Rosenberg et al., 1997).
While previous studies indicated that total memory B-cell
numbers were not completely restored after initiation of ART (Cagigi
et al., 2008; De Milito et al., 2001; Moir et al., 2008b), the group of
ART-treated subjects in this study had normal memory B-cell
frequencies. This was possibly due to longer and more sustained
viral suppression because the proportion of memory B-cells in treated
individuals depends on the degree of viral suppression (De Milito
et al., 2001). Whereas it has previously been reported that B-cell
responses to common recall antigens are frequently reduced in
advanced HIV disease (Janoff et al., 1991; Kroon et al., 2000; Lane
et al., 1983; Malaspina et al., 2005), memory B-cell responses to
inﬂuenza and Ttx were normal in the group of individuals with late
progressive disease in this study. This was not surprising as we
tolerated variability in natural exposure to inﬂuenza virus, inﬂuenza
and tetanus vaccine coverage and time point of booster immuniza-
tions. This approach may have obscured potential differences ininﬂuenza- and Ttx-speciﬁc immune responses between the groups.
However, it highlights the signiﬁcance of our ﬁndings with respect to
the HIV-speciﬁc memory B-cells because despite maximal recovery of
the total memory B-cells under ART and minimal damage to the
inﬂuenza and Ttx-speciﬁc memory B-cells, HIV-speciﬁc memory B-
cell responses were greatly reduced.
Gag and Env-speciﬁc antibodies were signiﬁcantly lower in the
ART-treated group indicating that short-lived plasma cells are
maintaining antibody titers in viremic individuals. It is well known
that Gag-speciﬁc antibodies decline during HIV disease progression
(Binley et al., 1997; Brown et al., 1995; Cheingsong-Popov et al., 1991;
Strathdee et al., 1995; Zwart et al., 1994) and the results of our study
are consistent with this ﬁnding. A potential mechanism for the decline
of Gag-speciﬁc antibodies in these studies that emerges from our
memory B-cell ﬁndings is that viral replication early in infection
induces vigorous memory B-cell and plasma cell activity. Subsequent
destruction of HIV-speciﬁc helper T-cells causes depletion of the HIV-
speciﬁc memory B-cells. As memory B-cells contribute to sustain
long-term antibody production through periodic differentiation into
antibody-secreting long-lived plasma cells (Crotty and Ahmed, 2004),
depletion of Gag-speciﬁc memory B-cells may reduce the ability to
renew the pool of HIV-speciﬁc plasma cells leading to a decline of
antibodies to levels maintained by long-lived plasma cells primed
early in infection.
As pointed out previously, Env-speciﬁc antibodies do not decline
spontaneously during disease progression indicating that Gag- and
Env-speciﬁc antibody responses are differentially regulated (Binley et
al., 1997; Bonsignori et al., 2009). The drop of Env-speciﬁc antibodies
in ART-treated individuals to basal levels indicates that Env-speciﬁc
antibodies are partially secreted by short-lived plasma cells. This is
consistent with recent observations that indicate maintenance of
Fig. 4. Titers of HIV-speciﬁc antibodies in infected individuals and correlation withmemory B-cell frequencies. (A) Midpoint titers of Gag/p24-speciﬁc antibodies; (B)midpoint titers
of Env/gp120-speciﬁc antibodies. Symbols represent values from individual subjects. Open symbols indicate antibody titers below 30. Bars indicate median values. Statistical p-
values were calculated using the Kruskal–Wallis (values in boxes) and Mann–Whitney test. (C) Gag/p24-speciﬁc memory B-cell frequencies of the subjects in the three untreated
groups are graphed with Gag-speciﬁc antibody titers; (D) Env/gp120-speciﬁc memory B-cell frequencies are graphed with corresponding antibody titers. Open symbols indicate
antibody titers below 30 or memory B-cell frequencies below 0.001%. The correlation coefﬁcient (r) and statistical signiﬁcance (p-value) were calculated using a non-parametric
Spearman test.
11Rapid CommunicationEnv-speciﬁc antibodies by short-lived plasma cells based on the short
half-life of the Env-speciﬁc antibody titer in ART-treated individuals
(Bonsignori et al., 2009).
A possible explanation how Env antigen-dependent antibody
titers are maintained in this situation is that Env activates B-cells in a
helper T-cell independent fashion. This has been considered previ-
ously (He et al., 2006) but the fact that Env does not have the
characteristics of a typical T-cell independent antigen and that T-cell
independent antibody responses are generally weak and IgM-
mediated argue against this hypothesis (Binley et al., 1997). Alter-
natively, antibodies are generated in a helper T-cell dependent
fashion. Possibly, the high variability of Env in contrast to Gag causes
occasional recruitment of new Env-speciﬁc helper T-cells resulting in
sufﬁcient Env-speciﬁc T-cell help to support the generation of
memory B-cells at quantities below the level of detection, and
short-lived plasma cells.
The preferential loss of HIV-speciﬁc memory B-cells may be
relevant to HIV disease progression. Although the study did not
speciﬁcally address memory B-cells for neutralizing antibodies, the
observation that gp120-speciﬁc memory B-cells were lost suggests
that the depletion includes memory B-cells and affects the plasma cell
pools relevant for viral inhibition. This facilitates genetic reversion of
the virus to variants that were previously encountered and likely
controlled by the immune system. This scenario has practicalimplications because it favors the concept of early antiviral interven-
tion to preserve the HIV-speciﬁc memory B-cells (Gourley et al.,
2004).
Materials and methods
Study participants and antigens
HIV-infected individuals with CD4+ T-cell counts above 350/μl,
patients with progressive disease and CD4+ T-cell counts below 200/
μl, and infected persons having experienced a fall in CD4+ T-cell
counts to below 200/μl or an AIDS-deﬁning illness that led to the
initiation of ART were enrolled in this study. CD4+ T-cell counts were
determined by ﬂow cytometry. Uninfected healthy individuals were
examined as controls. The study was approved by the Ethics
Committee of the Faculty of Medicine at the University of Leipzig
and informed consent was obtained from the study subjects.
Inﬂuenza-speciﬁc immunity was examined with recombinant
inﬂuenza H3N2 nucleoprotein as maltose binding protein (MBP)
fusion product. Tetanus toxoid (Novartis-Behring, Marburg, Ger-
many) was used to determine tetanus-speciﬁc responses. Immune
responses to HIV were tested with HIV-1W61D gp120 expressed in
Chinese hamster ovary cells (GlaxoSmithKline, Rixensart, Belgium)
and HIV-1HXB2 Gag/p24 expressed in Escherichia coli as MBP fusion
12 Rapid Communicationprotein (Reiche et al., 2009). MBP and bovine serum albumin served
as control antigens.
B-cell isolation and ﬂow cytometric characterization
Peripheral blood mononuclear cells (PBMCs) were prepared from
heparinized blood by density gradient centrifugation using a ﬁcoll
cushion (Histopaque, Sigma-Aldrich, Inc.). B-cells were isolated with
immunomagnetic anti-CD19 beads (Dynal® Pan CD19 kit, Invitrogen,
Inc.). Cells were resuspended in RPMI-1640medium (Invitrogen, Inc.)
supplemented with 10% fetal calf serum (Biochrom AG), 1% non
essential amino acids, 1% sodium pyruvate, 1% L-glutamin (Invitrogen,
Inc.), penicillin (100 IU/l, Jenapharm GmbH & Co. KG) and
streptomycin sulfate (100 mg/l, Pharma Wernigerode GmbH).
CD19-mediated selection of the cells had no negative effect on
subsequent measurements (data not shown). B-cell purity and the
distribution of B-cell subpopulations in PBMCs were analyzed by ﬂow
cytometry using anti-CD19, anti-CD20, anti-CD27 and anti-CD38
mAbs (BD Bioscience). Cell preparations contained on the average
97.2% B-lymphocytes.
Memory B-cell assay
PBMCs depleted of B-cells were treated with mitomycin C (50 mg/
l, Merck KgaA) and used as feeder cells. B-cells (2×105) and feeder
cells (1.8×106) were cultured for 6 days at 37 °C with a mixture of
mitogenic agents including pokeweedmitogen (PWM, Sigma-Aldrich,
Inc.), Staphylococcus aureus lysate (Sigma-Aldrich, Inc.), interleukin
(IL)-2 (Proleukin, Novartis AG), IL-10 (Hiss Diagnostics GmbH) and
phosphorothioated CpG ODN-2006 (Metabion GmbH) to induce
differentiation to plasma cells.
Antibody secretion was examined by ELISpot using 96-well
Multiscreen HA plates (Millipore, Inc.). Total numbers of antibody
secreting cells were determined with plates coated with goat anti-
human Ig recognizing IgG F(ab')2 (Dianova GmbH). Antigen-speciﬁc
responses were examined with plates coated with Env/gp120 (2 μg/
well), Gag/p24 (2 μg/well), inﬂuenza virus NP (NP, 2 μg/well) or
Ttx (1 μg/well) in quadruplicates. Wells coated with BSA (1 μg/
well) or MBP (1 μg/well) were used as controls. One hundred (Ig-
coated wells) or 50,000 (antigen-coated wells) cultured cells were
added and the plates incubated for 20 h at 37 °C. Plates were
washed and alkaline phosphatase-conjugated goat anti-human Ig
recognizing IgG, A and M (Dianova GmbH) was added for two
hours. The plates were developed using the AP Conjugate Substrate
Kit (Bio-Rad Laboratories, Inc.). Spots were counted using an AID
ELISpot 04 plate reader (Autoimmun Diagnostika GmbH). Spots in
wells with control proteins were subtracted from the number of
spots in wells with antigen.
The frequency of antigen-speciﬁc cells was calculated as the
percentage of total antibody-secreting cells according to the formula:
k Agspecific spots =
100
lg spots
 Ag spots − control spots
50;000
 100
No antibody secreting cells were detected with unstimulated B-cells
after culture for 6 days.
Antibody ELISA
96-well microtiter plates (Greiner Bio-One GmbH) were coated
overnight with recombinant protein (0.05–0.1 μg/well) in coating
buffer (0.2 M NaHCO3, pH 9.0). The plates were washed with
phosphate-buffered saline/0.05%Tween-20 (PBST) and blocked with
3% BSA in PBST. Sera were serially threefold diluted with PBST/BSA,
added to the wells and incubated for 2 h at 37 °C. HRP-conjugated
rabbit anti-human IgG (Dako GmbH, diluted 1:6,000) was added for1.5 h. Plates were incubated for 30 min at room temperature with
developing solution. The reaction was stopped with H2SO4 and the
OD at 450 nm was determined. Midpoint titers were calculated.
Midpoint titers were deﬁned as the reciprocal value of the serum
dilution at half maximal OD after background subtraction (Binley et
al., 1997). Pooled serum from HIV-infected individuals was used as
reference and tested in each series of experiments to adjust the half
maximal OD values. A ﬁctitious antibody titer of 10 was taken for
those sera that did not reach half-maximum OD at a dilution of
1:30.
Statistical analysis
Statistical analyses were performed using SPSS (version 12.0)
software. We used the Kruskall–Wallis test to determine signiﬁcance
of differences when comparing more than two study groups at a time.
If differences were signiﬁcant, pairwise comparisons were performed
with the Mann–Whitney test. A non-parametric Spearman test was
used for regression analysis to calculate correlations of memory B-cell
frequencies and antibody titers. The minimum level of signiﬁcance
was 0.05.
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